Nicox SA announced an extension of its cash runway, with an estimated cash position of €8.4 million as of 31 August 2026, sufficient to fund existing operations beyond Q1 2028. The company, an international ophthalmology firm, also provided a corporate and financial update, noting that the receipt of a milestone payment upon U.S. approval of its lead candidate NCX 470, with a PDUFA date of 30 April 2027, would fund operations into 2029, while subsequent royalties from a planned H2 2027 launch by partner Kowa could extend the runway substantially further. Additionally, Nicox announced management changes: Doug Hubatsch, formerly EVP and Chief Scientific Officer, has transitioned to Chief Scientific Advisor, and Siobhan Garbutt, VP and Head of Clinical Development, will lead the development team. The company continues to evaluate strategic growth opportunities, including potential collaborations or business combinations.
NicOx S.A.Cash runway extended beyond Q1 2028, with potential milestone and royalty payments extending further.
KOWA CO. LTD.